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&e airway epithelium stretches and relaxes during the normal respiratory cycle, and hyperventilation exaggerates this
effect, resulting in changes in lung physiology. In fact, stretching of the airways influences lung function and the
secretion of airway mediators, which in turn may cause a potentially injurious inflammatory response. &is aim of the
present narrative review was to illustrate the current evidence on the importance of mechanical stress in the path-
ophysiology of lung diseases with a particular focus on chronic obstructive pulmonary disease (COPD) and to discuss
how this may influence pharmacological treatment strategies. Overall, treatment selection should be tailored to
counterpart the effects of mechanical stress, which influences inflammation both in asthma and COPD. &e most
suitable treatment approach between a long-acting β2-agonists/long-acting antimuscarinic-agonist (LABA/LAMA)
alone or with the addition of inhaled corticosteroids should be determined based on the underlying mechanism of
inflammation. Noteworthy, the anti-inflammatory effects of the glycopyrronium/indacaterol combination on hyper-
inflation and mucociliary clearance may decrease the rate of COPD exacerbations, and it may synergistically improve
bronchodilation with a double action on both the cyclic adenosine monophosphate (cAMP) and the
acetylcholine pathways.
1. Introduction
&e bronchial epithelium preserves lung homoeostasis and
modulates airway inflammation; it plays a crucial role by
producing both pro- and anti-inflammatory cytokines,
affecting the migration of leucocytes in the airway sub-
mucosa and lumen and modulating the function of
myofibroblasts and airway smooth muscle cells [1]. &e
airway epithelium stretches and relaxes during the normal
respiratory cycle, and hyperventilation exaggerates this
effect, resulting in changes to lung physiology. In fact,
stretching of the airways influences lung function and the
secretion of airway mediators, which, in turn, may cause a
potentially injurious inflammatory response. Most exper-
iments investigating this effect have been performed in
static cultured cells, and evidence in dynamic models is
scant [1].
&is narrative review describes the current evidence on
the importance of mechanical stress in the pathophysiology
of lung diseases and chronic obstructive pulmonary disease
(COPD) and discusses how this can influence treatment
selection.
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2. Airways’ Mechanical Stress in Lung Diseases
&e role of mechanical stimuli in airway remodelling has
been hypothesized by Tschumperlin and Drazenmore than a
decade ago [2]. Unlike the common thinking of the period
that considered airway remodelling to be consequent to the
inflammatory milieu of the asthmatic setting, the authors
indicated cellular stresses in the constricted airway, com-
bined with a responsive cell population, as a plausible ex-
planation of the mechanically responsive nature of the
airway. &e profibrotic environment produced by me-
chanical stress applied to the airway epithelial cells, in the
absence of any inflammatory response, demonstrated the
role of mechanical stimuli in airway remodelling [2].
&omas et al. studied in vitro BEAS 2B cells, cyclically
stretched using the Flexercell system andmeasured the levels
of IL-8, RANTES protein, and RNA after variable elonga-
tions, rates, and duration of stretch [1]. In their study, the
authors used a Ras homologous-associated kinase (Rho
inhibitor) to assess the effect of blocking the downstream of
integrin signaling. Immunofluorescent staining of paxillin
was used to evaluate the effect of stretch on the distribution
of focal contacts and the organisation of the actin cyto-
skeleton. &e release of IL-8 induced by BEAS 2B cells was
increased by cytokine stimulation and stretch, whereas
RANTES levels in the cell supernatant decreased after stretch
in a dose-, time-, and rate-dependent manner. A rate of
elongation of 30% at 20 cycles/min for 24 h increased IL-8
levels by over 100% (p< 0.01). Conversely, blocking rho
kinase using Y-27632 inhibited the stretching effect on IL-8
release by the BEAS 2B cells. &e immunofluorescent
staining showed the disassembly of focal adhesions during
stretch, with a redistribution of paxillin to the perinuclear
region. According to the study results, bronchial epithelial
cell function is profoundly affected by stretching via the
activation of rho kinases, and mechanotransduction in
bronchial epithelial cells depends on a finely tuned co-
ordination of a focal adhesion turnover (assembly and
disassembly) [1].
In 2003, Tschumperlin et al. showed that bronchial
epithelial cells increase the steady state level of mRNA for
both ET-1 and ET-2, and they also increase the release of ET
protein and TGF-β2 from a preformed cell-associated pool
[3]. TGF-β2 and ETact both individually and synergistically
to promote fibrotic protein synthesis in reporter fibroblasts.
In fact, the elicited fibrotic protein synthesis in fibroblasts
occurring after mechanical stress of the bronchial epithelial
cells is significantly inhibited by combined treatment with
ETreceptor antagonists and a neutralizing antibody directed
against TGF-β2. &is study suggested that the bronchial
epithelium contributed to the fibrotic environment of the
airway wall and that the subepithelial fibrosis of the asth-
matic airway wall may be caused by the mechanical forces
accompanying bronchoconstriction.
Grainge et al. investigated the same phenomenon to
evaluate the effects of repeated experimentally induced
bronchoconstriction on airway structural changes in pa-
tients with asthma [4]. &ey randomly assigned 48 subjects
with asthma to one of four inhalation challenge protocols
involving a series of three challenges with one type of inhaled
agent presented at 48-hour intervals. &e two active chal-
lenges were with either a dust-mite allergen (which causes
bronchoconstriction and eosinophilic inflammation) or
methacholine (which causes bronchoconstriction without
eosinophilic inflammation); the two control challenges
(neither of which causes bronchoconstriction) were either
saline alone or albuterol followed by methacholine (to
control for non-bronchoconstrictor effects of methacho-
line). Bronchial biopsy specimens were obtained before
challenges and 4 days after completion of the challenges.
Overall, allergen and methacholine immediately induced
similar levels of bronchoconstriction. Eosinophilic in-
flammation of the airways increased only in the allergen
group, whereas both the allergen and the methacholine
groups showed significant airway remodelling not seen in
the two control groups. Subepithelial collagen-band thick-
ness increased by a median of 2.17 μm in the allergen group
(interquartile range (IQR): 0.70–3.67) and 1.94 μm in the
methacholine group (IQR: 0.37–3.24; p< 0.001 challenge
groups vs. control groups); periodic acid-Schiff staining of
epithelium (mucus glands) also increased, by a median of
2.17 percentage points in the allergen group (IQR: 1.03–4.77)
and 2.13 percentage points in the methacholine group (IQR:
1.14–7.96; p � 0.003 for the comparison with controls).
&ere were no significant differences between the allergen
and methacholine groups. &is study suggested that bron-
choconstriction induces epithelial stress and initiates a tissue
response that leads to structural airway changes. &e pre-
vention of bronchoconstriction itself should represent
therefore an important aim of asthma management, since
repeated epithelial stress may cause airways’ remodelling.
Noteworthy, airway inflammation also characterizes
COPD [5], as well as heavy smokers who do not develop
airflow obstruction. However, in the latter group, the in-
flammatory response is qualitatively similar to the one seen
in smoking-related COPD. A few studies showed a re-
lationship between the severity of airflow obstruction and
the degree of inflammation, supporting the hypothesis that
airway inflammation plays an important role in COPD. &e
airway wall exposed to inflammatory stimuli shows in-
creased levels of CD8+ T cells, macrophages, neutrophils,
and mast cells, whereas B cells are increased in more severe
COPD stages. &e main site of airflow obstruction in COPD
is represented by the small airways, the cytology of which is
difficult to access. However, the pattern of airway in-
flammation seen in larger airways, which are easily accessible
to bronchoscopic biopsy techniques, is essentially similar to
the one found in the smaller airways. Nevertheless, it is
difficult to precisely determine which are the most important
cells, cytokines and mediators involved in the process. Ul-
timately, understanding which pathway is important will
depend on intervention studies attempting to associate
changes in inflammation with clinical benefit.
&e role of bronchodilators is essential in the treatment
of COPD, and these drugs could play a primary role in terms
of airways mechanical stress modulation. Recently, Cazzola
et al. characterized the pharmacological interaction between
two bronchodilators as glycopyrronium bromide and
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indacaterol fumarate and identified the mechanisms leading
to the bronchorelaxant effect of this interaction [6]. &e
interaction between glycopyrronium and indacaterol on the
contractile tone of medium and small human isolated
bronchi was assessed by the Bliss Independence approach.
Glycopyrronium+ indacaterol synergistically inhibited the
bronchial tone (medium bronchi: +32.51%± 7.86%; small
bronchi: +28.46%± 5.35%; p< 0.05 vs additive effect). &e
maximal effect was reached 140min post-administration. A
significant synergistic effect was observed during 9 h after
administration on the cholinergic tone but not on the
histaminergic contractility (p< 0.05). Coadministration of
glycopyrronium and indacaterol reduced acetylcholine re-
lease from the epithelium but not from bronchi and en-
hanced cAMP levels in bronchi and epithelial cells (p< 0.05
vs control). &is effect was inhibited by the selective
KCa(++) channel blocker, iberiotoxin. &e role of cAMP-
dependent pathway was confirmed by the synergistic effect
elicited by the adenylate cyclase activator forskolin on
glycopyrronium (p< 0.05 vs additive effect), but not on
indacaterol (p> 0.05 vs additive effect), with regard to the
bronchial relaxant response and cAMP increase. &ese
findings suggested that glycopyrronium/indacaterol co-
administration leads to a synergistic improvement of
bronchodilation by increasing cAMP concentrations in both
airway smooth muscle and bronchial epithelium and by
decreasing acetylcholine release from the epithelium.
3. Clinical Evidence
Small airways play an important role in the pathogenesis of
COPD, and their functional evaluation relies on specific lung
functional tests, known from many years [7]. Taking in
account these pathophysiological evidence, it should be
underlined that further damage and substantial in-
flammatory reactions may occur when small airway collapse
is enhanced by increased surface tension [8], thus sup-
porting the hypothesis that the cyclic opening and closing of
small airways during tidal breathing causes lung injury in
man [9]. More recently, Pecchiari et al. demonstrated that
airway closure involves a substantially greater fraction of the
resting tidal volume in a population of severe and very severe
COPD patients. &erefore, cyclic opening and closure could
perpetrate the damage to normal airways as it happens in
already altered airways [10].
A landmark trial has recently investigated whether de-
struction of the terminal and transitional bronchioles (the
first generation of respiratory airways) occurs before or in
parallel with emphysematous tissue destruction [11]. In this
cross-sectional analysis, a novel multiresolution CT imaging
protocol was applied to tissue samples of smokers with
normal lung function (controls, n� 10) and patients with
mild COPD (Global Initiative for Chronic Obstructive Lung
Disease (GOLD) stage 1, n� 10), moderate COPD (GOLD 2,
n� 8), or very severe COPD (GOLD 4, n� 6), with cen-
trilobular emphysema. Patients with GOLD 1 or GOLD 2
COPD and smokers with normal lung function had un-
dergone lobectomy and pneumonectomy, and patients with
GOLD 4 COPD had undergone lung transplantation. Lung
tissue samples were used for stereological assessment of the
number and morphology of terminal and transitional
bronchioles, airspace size (mean linear intercept), and al-
veolar surface area. &e 34 lung specimens provided 262
lung samples. Compared with control smokers, the number
of terminal bronchioles decreased by 40% and 43% in pa-
tients with GOLD 1 and GOLD 2 COPD (p � 0.014 and
p � 0.036, respectively), whereas the number of transitional
bronchioles decreased by 56% and 59% in patients with
GOLD 1 and GOLD 2 COPD, respectively (both
p � 0.0001). &e alveolar surface area decreased by 33% and
45% in patients with GOLD 1 and GOLD 2 COPD
(p � 0.019 and p � 0.0021, respectively). In several cases,
significant loss of terminal and transitional bronchioles was
noted also in case of normal alveolar surface area, and all
these pathological changes correlated with lung function
decline. &e remaining small airways showed thickened
walls and narrowed lumens, becoming more and more
obstructed with increasing COPD GOLD stage. &e authors
concluded that small airways disease is a pathological feature
in mild and moderate COPD. Importantly, this study em-
phasizes that early disease-modifying interventions might be
necessary for patients with mild or moderate COPD.
Barnes et al. tested the hypothesis that inhaled combined
long-acting β2-agonist (salmeterol) and corticosteroid
(fluticasone propionate) may reduce inflammation [5].
Bronchial biopsies and induced sputum from 140 current
and former smokers with moderate-to-severe disease were
randomized in a 13-week double-blind study to placebo
(n� 73) or salmeterol/fluticasone propionate 50/500mg
(n� 67) twice daily and repeated at 12weeks (biopsy) or at 8
and 13weeks (sputum). After adjustment for multiplicity,
the active treatment group was compared with the placebo
group for median change from baseline in the numbers of
biopsy CD8+ and CD68+ cells/mm2 and sputum neutro-
phils. Combination therapy was associated with reduced
CD8+ cells in biopsy (− 118 cells/mm2; 95% confidence in-
terval (CI): − 209 to − 42; p � 0.02), a 36% difference over
placebo (p � 0.001). CD68+ cells were unaffected by the
combination treatment. Sputum differential (but not total)
neutrophils decreased progressively, and at week 13, they
were significantly reduced with the combination treatment
(median treatment difference: 8.5%; 95% CI: 1.75–15.25%;
p � 0.04). &e combination therapy also significantly re-
duced biopsy CD45+ and CD4+ cells and cells expressing
genes for tumor necrosis factor-alpha and IFN-gamma and
sputum total eosinophils (all p≤ 0.03). &ese anti-in-
flammatory effects were accompanied by a 173-ml im-
provement in pre-bronchodilator forced expiratory volume
in 1 s (FEV1; 95% CI: 104–242; p< 0.001). Overall, the
combination of salmeterol and fluticasone propionate
showed a broad spectrum of anti-inflammatory effects in
both current and former smokers with COPD, which may
contribute to its clinical efficacy.
Pecchiari et al. investigated the acute effects of tio-
tropium (18 μg) and indacaterol (150 μg) on closing volume
(CV) and ventilation inhomogeneity in 51 stable patients
with moderate to very severe COPD [12]. Patients un-
derwent body plethysmography, arterial blood gas analysis,
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negative expiratory pressure to discriminate the presence of
tidal expiratory flow limitation (EFL), dyspnea assessment,
and simultaneous recording of single-breath nitrogen
washout (SBN2) test and transpulmonary pressure-volume
curve (PL-V), before and 1 h after drug administration.
Except for vital and inspiratory capacity, the effects pro-
duced by indacaterol on each variable did not differ from
those caused by tiotropium. Bronchodilators significantly
decreased the slope of phase III and CV (− 5± 4 and
− 2.5± 2.1%, respectively, both p< 0.001), with an increase in
both the slope and the height of phase IV and of the ana-
tomical dead space. Arterial oxygen pressure and saturation
significantly improved (3± 3mmHg and 2± 2%, re-
spectively, both p< 0.001), and their changes negatively
correlated with those of phase III slope (r� − 0.659 and
r� − 0.454, respectively, both p< 0.01). &e vital capacity
increased substantially, but the PL-V/VC curve above CV
was unaffected. &e authors concluded that both muscarinic
antagonists and β-adrenergic agonists provide airways
bronchodilation by improving the mechanical properties of
peripheral airways and the extent of their closure, with
minor effects on critical closing pressures, and positively
affecting gas exchange. Previously, Santus et al. evaluated the
effect of a 4-week treatment with two different broncho-
dilators of common practice in COPD treatment, on the
production of reactive oxygen species (ROS), such as su-
peroxide anions, and of leukotriene B4 (LTB4) by peripheral
blood neutrophils obtained from COPD patients [13]. &ey
enrolled 24 COPD outpatients, who were randomized to
receive either formoterol (12 μg twice daily) or tiotropium
(18 μg once daily). Peripheral blood neutrophils were ob-
tained at the start and at the end of the treatment, and
production of superoxide anions and of LTB4 was evaluated.
&e authors demonstrated a decrease in the unstimulated
production of superoxide by isolated neutrophils in both
groups and a modulation of LTB4 production for tiotropium
only, whereas formoterol caused an increased production of
superoxide in response to the chemotactic factor N-formyl-
L-methionyl-L-leucyl-phenylalanine (fMLP), when com-
pared with values obtained before treatment [13]. &ese data
sustained the notion that, in COPD patients, tiotropium has
a better anti-inflammatory activity profile compared with
formoterol. &e latter results sustain the evidence that tio-
tropium can modulate the Ach-mediated LTB4 release, thus
indirectly influencing the granulocyte chemotactic activity
and in human airways [14].
&e potential ancillary non-bronchodilator properties of
tiotropium have been extensively investigated in vitro and in
animal models [15, 16]. In fact, tiotropium demonstrated a
potential role in modulating the neutrophilic airway in-
flammation and neutrophil adhesion by controlling the
release of TGF-β [17]; moreover, tiotropium was shown to
modulate the pro-inflammatory effects of IL-17 induced
release of IL-8 in bronchial epithelial cells [18], to have a
positive effect on lung fibroblast proliferation [19], and to
modulate airway inflammation in a model of rhinovirus
infection by inhibiting the activation of nuclear factor (κ)B
proteins [20]. Tiotropium may also counteract to some
extent the nonneuronal acetylcholine mediated production
of &17 cells in patients with COPD [21] and inhibit the
IL-13-induced goblet cells metaplasia in healthy airway
epithelial cells [22].
Santus and coworkers recently tested whether LABAs
can affect the exhaled alveolar fraction of nitric oxide
(CANO), an indirect inflammatory biomarker of the pe-
ripheral lung, correlating CANO with lung mechanics in
patients with COPD [23]. &e study was a two-center,
randomized, double-blind, crossover study including 45
COPD patients with moderate-to-severe airflow obstruction
after a period of pharmacological washout. In the study,
multiflow exhaled fraction of nitric oxide (FeNO), pleth-
ysmography, lung diffusion capacity for carbon monoxide
(DLCO), SBN2 test, and dyspnea were measured in a
crossover manner at baseline and 30, 60, and 180min after
the administration of salmeterol (Sal) or formoterol fu-
marate (FF). At baseline, CANO correlated with airway
resistances (r� 0.422), residual volume/total lung capacity
(RV/TLC; r� 0.375), transfer factor (KCO; r� − 0.463), and
FEV1 (r� − 0.375, all p< 0.01). After LABA administration,
FeNO was significantly reduced at 180min, without dif-
ferences between FF and Sal. Moreover, the authors reported
a significant reduction in CANO at 60 and 180min com-
pared with baseline for both FF and Sal (p< 0.01 and
p< 0.05, respectively), and the changes in CANO being
correlated with improvements in VC (r� − 44; p< 0.001) and
RV/TLC (r� 0.56; p< 0.001) but not FEV1. Importantly, the
levels of CANO appeared to be directly associated to the
magnitude of peripheral airway dysfunction in COPD, since
LABA administration reduced the CANO levels and the
reduction was associated with improvements in functional
parameters reflecting air trapping.
At present, the available clinical results support the
possibility that the effects of LABA/LAMA combinations on
hyperinflation and mucociliary clearance may contribute to
decreased COPD exacerbations [24]. Although preclinical
studies suggest LABAs and LAMAs have anti-inflammatory
effects, such effects have not yet been demonstrated in
patients with COPD.
However, preliminary in vitro findings suggest that the
specific LABA/LAMA combination of glycopyrronium/
indacaterol may synergistically improve bronchodilation by
increasing cAMP concentrations in both airway smooth
muscle and bronchial epithelium and by decreasing ace-
tylcholine release from the epithelium [6].
4. Implications for Clinical Practice
According to the available evidence, a careful evaluation on
the pathophysiological mechanisms leading to inflammation
in COPDmay have a major role in the selection of treatment
(Figure 1).
Briefly, clinicians should look for direct and/or indirect
evidence of inflammation (blood eosinophil counts, disease
exacerbations, and functional decline) and of its origin,
either typical (cellular and/or molecular, “aborigine”) or
secondary to mechanical stress (“stretch and strain”), and
according to the findings, introduce the proper treatment
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with a combination of LABA/LAMA with or without in-
haled corticosteroids.
&e noncholinergic nonadrenergic system (NANC)
should be also taken in consideration. NANC, particularly as
an additional branch of the cholinergic system, is the
nonneuronal cholinergic system expressed in nearly all cell
types present in the bronchial tree, with specific regards for
distal airways. When NANC is activated, it contributes to an
increased cholinergic tone in the respiratory system in-
ducing different pathophysiological processes, such as in-
flammation, remodelling, chronic cough, and mucus
hypersecretion [25]. In clinical practice, in view of the
aforementioned evidence, the application of a selective
LAMA as the initial treatment choice in patients with COPD
could thus exert some positive non-bronchodilator effects,
acting on neuronal and nonneuronal Ach-mediated in-
flammatory pathways. &is may have an impact on the
regional inflammatory environment, with additive beneficial
effects on the modulation of the “traditional” inflammatory
pathways together with the proven bronchorelaxant effect in
patients with COPD.
Additionally, a global evaluation including clinical,
functional, and morphological assessment by means of
complete lung function tests, SBN2 test, DLCO, and chest
CT scan should be performed before the therapeutic choice.
&e flow chart does not consider initial and less severe
COPD stages, where only a single bronchodilator may be
indicated.
Indeed, in COPD patients, it is widely accepted that
exacerbations, eosinophilia, and functional decline ulti-
mately leading to inflammation. However, the underlying
mechanism that contributes most to the inflammatory
process can be either molecular or secondary to mechanical
stress. In the latter case, inhaled corticosteroidsmay not have
a major role in the treatment paradigm; on the other hand,
therapy with a LABA/LAMA combination will appear more
suitable. Patients on long-term treatment with ICS-con-
taining regimens should thus be always evaluated for ICS de-
escalation or withdrawal. To date, the direct evidence of the
clinical and pathophysiological effects of ICS withdrawal in
patients with COPD is limited but consistent, and this has
led to the publication of numerous de-escalating algorithms
[26–29] &e indirect proof that ICS withdrawal did not
increase the exacerbation rate was shown by the subgroup
analysis of a recently published real life, noninterventional,
longitudinal prospective cohort study conducted in primary
and secondary care patients with COPD [30]; these results
were confirmed in a subgroup analysis of the CRYSTAL
study, a pragmatic trial that shows that symptomatic patients
with moderate COPD switched from a treatment with
LABA/ICS to indacaterol/glycopyrronium which demon-
strated a significant increase in FEV1 (71mL, p< 0001) and
TDI score (+1.10 units, p< 0.0001) [31]. In 2014, Rossi et al.
performed a six-month randomized double-blind double-
dummy parallel group study in which patients with mod-
erate COPD without exacerbations in the previous year were
switched from salmeterol/fluticasone 50/500 mcg BID to
LAMA/LABA and 
ICS
ICS withdrawal
Evidence? Direct: limitedIndirect: increasing
LAMA/LABA
Classic:
cellular/molecular
“ab origine”
Clinical, functional, and morphological evaluation:
Subsequent to
AW mechanical
stress, stretch, and strain
NANC system NANC system
Exacerbations
Blood eosinophils
Functional decline
LABA/ICS-LAMA/LABA/ICS
or
LAMA/LABA
AW
inflammation
COPD inhaled treatment
-plethysmography; SBN2 test; CV/CC
-DLCO
-chest CT scan
Figure 1: Inhalation treatment selection in COPD according to the underlying mechanism of inflammation. AW: airway flow.
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indacaterol 150mcg, without any sign of loss of efficacy in
the indacaterol-treated group [32]. Comparable results were
observed in a six-month real life study in which patients with<2 exacerbations in the previous year and moderate COPD
underwent a de-escalation therapy from ICS-containing
regimens to long-acting bronchodilators only [33]. More
recently, Kaplan and colleagues demonstrated that a direct
switch to indacaterol/glycopyrronium in symptomatic pa-
tients with moderate-to-severe COPD despite treatment
with tiotropium alone or the combination of salmeterol/
fluticasone was safe and provided clinically significant im-
provements in lung function, quality of life, and disease-
related symptoms [34].
&e WISDOM study [35] first demonstrated that ICS
withdrawal in patients with severe COPD and at least one
exacerbation in the previous year did not increase the ex-
acerbation frequency in patients treated with the association
of indacaterol/glycopyrronium. A post hoc subgroup anal-
ysis of the trial found that patients with <2% of blood eo-
sinophils were those that benefited most of the ICS
withdrawal in terms of exacerbation risk [36]. &ese results
were prospectively confirmed in the SUNSET study [37], a
26-week randomized double-blind triple-dummy clinical
trial; patients with COPD at low risk of exacerbations in
triple therapy with tiotropium and salmeterol/fluticasone
were randomized to directly switch to indacaterol/glyco-
pyrronium or to continue the triple therapy. Again, patients
with baseline ≥300 blood eosinophils/μl presented greater
lung function loss and higher exacerbation risk. We
therefore suggest that, upon a meticulous assessment of the
clinical history and confirmation of the diagnosis, in all
COPD patients, independent of the degree of airflow ob-
struction, that show clinical stability in the last two years and
without elevated blood eosinophils (i.e. ≥400 cells/μl), the
withdrawal of ICS and the initiation of a LABA/LAMA
treatment should always be considered. To date, high quality
and direct evidence suggesting if twice daily or once daily
dosing regimens for approved fixed dose LABA/LAMA
combinations is lacking. In terms of efficacy, indirect
comparisons performed by means of systematic reviews and
meta-analyses did not point out any clinical significant
difference [38, 39]. A “gradient of effectiveness” of LABA/
LAMA combinations in terms of trough FEV1 has been
postulated by Calzetta et al. in their meta-analysis [38], with
the first place shared by two different dosing regimens (i.e.,
once and twice daily). Taking in consideration the great
impact of adherence to inhaled treatment on patient-related
outcomes [40], once-daily dosing regimens had been ad-
vocated to favor adherence among patients with COPD;
however, this hypothesis is only weakly sustained by clinical
evidence [41, 42]; accordingly, twice-daily LABA/LAMA
combinations should sustain an increased symptom control
through night-time and on awakening [43], but direct and
conclusive comparator studies to assess any difference in
dosing regimens are currently lacking.
A proper clinical and pathophysiological assessment of
disease and patient’s characteristics should therefore always
serve as the guidance for treatment selection.
5. Conclusion
It has been shown that mechanical stress plays an important
role in the pathophysiology of lung diseases and COPD.
&us, treatment selection should be tailored to counterpart
the effects of mechanical stress, which influences in-
flammation in COPD and asthma. &e most suitable
treatment approach between a LABA/LAMA alone or with
the addition of inhaled corticosteroids should be determined
based on the underlying mechanism of inflammation.
Noteworthy, the anti-inflammatory effects of the glyco-
pyrronium/indacaterol combination on hyperinflation and
mucociliary clearance may decrease the rate of COPD ex-
acerbations, and it may synergistically improve broncho-
dilation with a double action on both the cAMP and the
acetylcholine pathways. Moreover, evidence suggests that a
tailored therapeutic approach with bronchodilators may be
relevant also in asthma, in order to prevent the remodelling
of the asthmatic airway wall caused by the mechanical stress
associated with bronchoconstriction.
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